B.C.'s health minister to raise alarm over baby-gender test [Canada]
By Vancouver Sun,
Vancouver Sun
| 08. 15. 2005
B.C. Health Minister George Abbott says he plans to contact his federal counterpart, Ujjal Dosanjh, this week to express his alarm about a test kit available for sale over the Internet that apparently makes it possible for a woman to find out the gender of a fetus as early as five weeks into her pregnancy.
"This is something that is of much concern to me," he said in an interview Sunday. "Gender testing should only be done in early stage pregnancy when it's medically necessary."
He will also bring his concerns about the test to a scheduled meeting of provincial and territorial health ministers in the fall if necessary, he said.
Not only is the province concerned about the possibility that the test could be used by couples to terminate a pregnancy based on the sex of the embroyo, there is no way to determine the reliability of the testing kit.
"We really have no way of knowing of the quality of the kits and whether in fact the predictability of the kits and accuracy of the kits ....
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...